CureVac (NASDAQ:CVAC - Get Free Report) traded down 4.8% on Monday . The company traded as low as $2.77 and last traded at $2.77. 182,617 shares traded hands during trading, a decline of 77% from the average session volume of 806,119 shares. The stock had previously closed at $2.91.
Wall Street Analysts Forecast Growth
Separately, Guggenheim reissued a "neutral" rating on shares of CureVac in a research note on Friday, April 5th.
View Our Latest Report on CVAC
CureVac Trading Down 8.9 %
The company has a quick ratio of 3.41, a current ratio of 3.56 and a debt-to-equity ratio of 0.06. The company has a fifty day moving average of $3.25 and a 200-day moving average of $4.39.
Institutional Investors Weigh In On CureVac
Several institutional investors and hedge funds have recently modified their holdings of CVAC. Ballentine Partners LLC purchased a new stake in CureVac during the 1st quarter worth about $38,000. China Universal Asset Management Co. Ltd. increased its holdings in CureVac by 95.6% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 5,738 shares of the company's stock worth $39,000 after purchasing an additional 2,804 shares during the period. Vontobel Holding Ltd. acquired a new position in shares of CureVac during the 4th quarter worth about $45,000. Optiver Holding B.V. boosted its position in shares of CureVac by 2,407.0% during the 3rd quarter. Optiver Holding B.V. now owns 6,844 shares of the company's stock worth $47,000 after acquiring an additional 6,571 shares in the last quarter. Finally, Pathstone Holdings LLC acquired a new position in shares of CureVac during the 4th quarter worth about $55,000. Hedge funds and other institutional investors own 17.26% of the company's stock.
About CureVac
(
Get Free Report)
CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202, a prophylactic mRNA-based vaccine, which has completed Phase 1 clinical trial for rabies virus glycoprotein; and CVSQIV, which is in Phase 1 clinical trial against influenza, as well as vaccine for lassa fever, yellow fever, respiratory syncytial virus, rotavirus, malaria, and universal influenza.
See Also
Before you consider CureVac, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CureVac wasn't on the list.
While CureVac currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.
Get This Free Report
